RxDoctor Payments Data

Rachel Pippenger, NP

Family · Nappanee, INNPI 1164893616

Payments from drug & device makers

$1,613in general payments, 2019–2025

Across 96 payments — averaging $16.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$361
  • Pfizer$276
  • AstraZeneca$240
  • Novo Nordisk$182
  • Lilly USA, LLC$104
  • GSK$91
  • plus $359 from 12 others

What the payments were for

  • Food & beverage$1,60199%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,613 in reported general payments places this provider in the 75th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$28,386
Medicare patients
173
Services billed
486

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide41$55,858
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$34,917
OzempicSemaglutide14$14,760
FarxigaDapagliflozin Propanediol12$13,608
NexlizetBempedoic Acid/Ezetimibe12$4,704
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$3,662
Humulin 70-30Insulin Nph Hum/Reg Insulin Hm11$1,306
Albuterol Sulfate HfaAlbuterol Sulfate44$1,008
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen61$977
Fluticasone Propionate62$902
Duloxetine Hcl39$720
Atorvastatin Calcium121$705
Levothyroxine Sodium65$641
Doxycycline Hyclate66$598
Ibandronate Sodium21$581

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Humulin 70-30$104$57,16452 claims
GSKTrelegy Ellipta$91$34,91729 claims
Novo NordiskOzempic$182$14,76014 claims
AstraZenecaFarxiga$240$13,60812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,392 family providers in Indiana.

Other family in Nappanee

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →